



Versartis  
Investor Relations Department  
4200 Bohannon Drive  
Suite 250  
Menlo Park, CA 94025  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: VSAR

Last Trade:	1.83
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.03  (-1.351%)
Day Range	1.75 - 1.90
52-Week Range	1.60 - 24.00
Volume	710,407

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


## Company Profile

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry.

Somavaratan (VRS-317) is an investigational, novel, long-acting form of recombinant human growth hormone (rhGH) initially in development for the treatment of GHD in children and adults.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Oct 26, 2017*

[Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)

*Oct 26, 2017*

[Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions](#)

*Sep 21, 2017*

[Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint](#)

*Sep 7, 2017*

[Versartis' Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017](#)

*Sep 5, 2017*

[Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 10, 2017*

[Annual Report \(10-K\)](#)

*Aug 14, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 7, 2017*

[Quarterly Report \(10-Q\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)